POTP Point Therapeutics (MM)

Point Therapeutics, Inc. (NASDAQ: POTP) today reported the upcoming presentation of preclinical data at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) taking place in Los Angeles, California, April 14-18, 2007. The AACR poster presentations report on preclinical studies on talabostat�s novel mechanism of action. Additional details for the AACR presentations are as follows: Presentation Date and Time: Monday, April 16, 2007, 8:00 AM -12:00 PM PT Abstract #1894: Immune mechanisms of action of talabostat: a dipeptidyl peptidase targeted anti-tumor agent Presentation Date and Time: Wednesday, April 18, 2007, 8:00 AM -12:00 PM PT Abstract #5622: The anti-tumor potential of inhibitors of the DASH proteases in a mouse model of human breast cancer The posters associated with the abstracts will be available on the Point Therapeutics� web site at www.pther.com immediately following their presentation. About Point Therapeutics, Inc.: Point is a Boston-based biopharmaceutical company currently studying its lead product candidate, talabostat, in two Phase 3 double blind, placebo-controlled trials in non-small cell lung cancer and in a Phase 2 trial in combination with gemcitabine in metastatic pancreatic cancer. Point has also studied talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia.